Applications of 2'-Chloro-2'-Deoxyuridine in Industrial Manufacturing

As a specialized manufacturer, we supply high-purity 2'-Chloro-2'-Deoxyuridine to major segments of the fine chemicals and life sciences industries. Our customers use this raw material in strict accordance with regulatory, technical, and commercial requirements. The diverse downstream uses reflect specific synthesis needs, production protocols, and finished product specifications.

1. Pharmaceutical Antiviral Drug Intermediate Synthesis

Pharmaceutical producers integrate 2'-Chloro-2'-Deoxyuridine as a key intermediate in several nucleoside analogue drug synthesis processes for antiviral therapeutics. This raw material undergoes further derivatization or functional group transformation steps and becomes core to the scaffold of finished antiviral agents active against viruses such as herpes simplex. Customers demand consistent material quality supporting cGMP downstream synthesis, controlling for trace impurities and batch quality. End users proceed with scale-up to active pharmaceutical ingredient (API) post-derivatization.

Industry compliance standards

• US FDA cGMP (21 CFR Part 210/211) for pharmaceutical intermediates
• ICH Q7: Good Manufacturing Practice for Active Pharmaceutical Ingredients
• European Pharmacopoeia monographs (where applicable)
• Chinese Pharmacopoeia (for products in China market)

Typical usage ratio

• 0.5–5 molar equivalents based on target nucleoside product
• Adjusted for conversion yield; higher ratios if recovery/purification yield is lower
• Process-specific adjustments depend on protection/deprotection schemes

Downstream process integration

• Batch-wise or continuous flow alkylation, halogenation, or glycosylation reactions
• Introduced at early to mid-stages of multistep synthesis for API preparation
• Subject to in-process quality control and trace impurity removal pre-API isolation

Final product types

• Nucleoside antiviral active pharmaceutical ingredients (APIs)
• Bulk pharmaceutical intermediates for licensing supply chains
• Finished oral or parenteral dosage antiviral medications (via downstream formulation)
• Reference standards and research-grade nucleoside analogues

2. Radiolabeled Probe Precursor in Molecular Biology

Manufacturers serving the advanced molecular biology markets use this material as a sugar-base building block for preparing radiolabeled nucleoside probes. The 2'-chloro group is specifically amenable to targeted isotopic labeling and subsequent enzymatic incorporation into oligonucleotide strands. Downstream integration demands rigorous control in radiochemistry and compliance with isotope handling protocols. Products reach the market through specialized customers in diagnostics and pharmaceutical R&D.

Industry compliance standards

• ISO 13485:2016 for in vitro diagnostic manufacturing
• US NRC and equivalent local regulations for handling radiolabeled substances
• GMP for radiopharmaceutical intermediates (PIC/S guidance where relevant)
• Quality assurance per ANSI N43.1 for safe isotope laboratory materials

Typical usage ratio

• 0.1–1.5 equivalents in precursor synthesis per labeled probe batch
• Adjusted according to radiochemical yield requirements and downstream enzymatic efficiency
• Micro-scale to gram-scale processing depending on application (assay vs. clinical research)

Downstream process integration

• Initial building block in nucleoside radiolabel synthesis
• Introduced into site-specific nucleoside modifications via chemical or enzymatic steps
• Finished labeled intermediate purified by HPLC or preparative chromatography

Final product types

• Radiolabeled oligonucleotide probes for molecular diagnostics
• Research reagents for DNA/RNA synthesis validation
• Clinical tracers for pharmaceutical and biological assay development
• Custom-labeled nucleoside libraries for academic and industry research

3. Custom Oligonucleotide Synthesis for Diagnostic Reagents

Oligonucleotide manufacturers require 2'-Chloro-2'-Deoxyuridine as a modified base, supporting synthesis of oligos with increased enzymatic resistance and altered hybridization characteristics. It is introduced via automated solid-phase oligonucleotide synthesis, necessitating precise phosphoramidite chemistry adaptation for the 2'-chloro moiety. High-purity supply validates cGMP manufacturing lines for producing diagnostic-grade compounds under ISO-accredited QC.

Industry compliance standards

• ISO 9001:2015 and ISO 13485:2016 for oligonucleotide-based reagent manufacturing
• US FDA 21 CFR Part 820 if reagents serve as medical device components
• European IVD-R for diagnostic applications placed on the EU market
• Internal QC according to customer-specific monograph and raw material traceability requirements

Typical usage ratio

• Single modified base per target sequence, or 1–10% substitution depending on oligonucleotide design
• Higher ratios used to improve nuclease resistance in specific probe applications
• Adjustment based on melting temperature and hybridization target

Downstream process integration

• Integrated as a custom base during automated solid-phase synthesis cycles
• Adapts to standard phosphoramidite chemistry with minor protocol modifications for 2'-chloro functionality
• Subjected to trityl analysis, mass spectrometry, and purity confirmation prior to dispatch

Final product types

• Custom diagnostic oligonucleotides and hybridization probes
• Primers for PCR/qPCR with increased stability
• RNA interference reagents with modified resistance
• DNA-based biosensor components

4. Raw Material for Modified Nucleic Acid Polymer Synthesis

Producers of specialty nucleic acid polymers, including DNA and RNA analogues for research and gene therapy, source this compound for introducing halogenated functionality into polymer backbones. The 2'-Chloro-2'-Deoxyuridine functions as a monomer in co-polymerization reactions using enzymatic or chemical polymerase systems, enabling production of nucleic acid strands with custom backbone modification. Exact ratios and integration steps are determined by process chemistry and desired physical properties of final polymers.

Industry compliance standards

• REACH registration for specialty chemical monomers (EU market)
• ISO 9001:2015 for supplier quality management
• GMP guidelines for materials destined for clinical research (USP <1079>, EudraLex Volume 4)
• Analytical validation for polymer quality (e.g., HPLC-MS, NMR characterization)

Typical usage ratio

• 1–20% molar substitution within DNA/RNA analogue backbone for research polymer batches
• Exact ratio controlled for backbone modification and downstream physical property tuning
• Quality testing determines incorporation efficiency and polymer homogeneity

Downstream process integration

• Monomer co-feeding during enzymatic or solid-phase nucleic acid polymerization
• Material introduction controlled in automated reactors or batch systems under anhydrous conditions
• Residual monitoring and removal post-polymerization to ensure compliance with target purity profiles

Final product types

• Base-modified DNA and RNA polymers for research reagents
• Gene editing research tools with enhanced properties
• Specialty nucleic acid drugs under early-phase clinical study (non-commercial)
• Reference polymers for physical/chemical property studies